In March 2026, Roche reported that the Phase 2 ZUPREME-1 trial produced mean body-weight reductions of up to 10.7% at week 42 versus 1.7% with placebo under the reported analysis
We know we cant simply deliver the enzyme into the blood and have it access the brain, so we try to devise methods to overcome this problem, she explains
What the research supports: Semaglutide (GLP-1 medication): Clinical trials show meaningful average weight loss for many people when used with lifestyle support and medical monitoring
"Optic neuropathy as a presenting feature of vitamin B-12 deficiency: A systematic review of literature and a case report"
[DOI] [PMC free article] [PubMed] [Google Scholar] 44.Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al